Pharma: Other News To Note
Friday, February 10, 2012
Merck and Co. Inc., of Whitehouse Station, N.J., warned U.S. physicians that a recent pharmacokinetic study in healthy volunteers showed hepatitis C protease inhibitor Victrelis (boceprevir) may reduce the efficacy of ritonavir-boosted HIV protease inhibitors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.